HCV induced thrombocytopenia in Punjab,Pakistan
Abstract
Abstract Views: 154
HCV is the main causal agent of blood transmitted hepatitis which can lead to the development of liver cirrhosis and hepatocellular carcinoma in infected persons. In patients with HCV related hepatic diseases, immune mediated responses against surface antigens can cause the destruction of platelets. Despite a high prevalence of HCV and its extrahepatic presentations, reports on platelet count in HCV infected patients are scarce. Therefore, this study aims to determine thrombocytopenia in suspected HCV patients in Lahore, Pakistan. It also aims to find out its association with other factors such as age, gender, viral load and ALT. For this cross-sectional retrospective study, blood samples were collected from 200 suspected HCV patients, including both male and female patients, who were between 20-69 years of age. Serum ALT levels were determined and HCV antibodies were detected. Thrombocytopenia was defined as the platelet count below 150,000/μL. Pearson’s correlation was used to find out the statistically significant relationship of platelet count with age, viral load and ALT. Platelet count varied between 29.00- 402.00 x 103 /μl. The mean platelet count was 206.87 ± 83.88 x 103 /μl. Platelet count less than 150 x 103/μl was considered as thrombocytopenia, whereas platelet count measuring above 150 x 103/μl was considered normal. It was normal in 72% patients and low in 28% patients. There was a negative correlation between age and platelet count which was statistically significant (r = -0.304, N= 200, p = 0.00012).
Copyright (c) The Authors
Downloads
References
. Allain J-P. Transfusion risks of yesterday and of today. Transfus Clin Biol. 2003;10(1): 1-5.
. World Health Organization. Global report on access to hepatitis C treatment: focus on overcoming barriers. Geneva: World Health Organization; 2016.
. Vos T, Barber, RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995): 43-800.
. Lanini S, Easterbrooke PJ, Zumla A, et al. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22(10): 833-838.
. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1): S45-S57.
. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promotion Int. 2004;19(1): 95-103.
. Dedania B, Wu GY. Dermatologic extrahepatic manifestations of hepatitis C. J Clin Transl Hepatol. 2015;3(2): 127.
. Galossi A, Guarisco R, Bellis L, Puoti C. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis. 2007;16(1): 65.
. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum. 1999;42(10): 2204-2212.
. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. J Hepatol. 2006;44(1): 15-22.
. Hamaia S, Li C, Allain J-P. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood. 2001;98(8): 2293-2300.
. Panasiuk A, Prokopowicz D, Zak J, Matowicka J-K, Osada J, Wysocka J. Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology. 2001;48(39): 818-822.
. Pugliese A, Gennero L, Cutufia M, et al. HCV infective virions can be carried by human platelets. Cell Biochem Funct. 2004;22(6): 353-358.
. de Almeida AJ, Campos-de-Magalhaes M, Brandao-Mello CE, de Oliveira RV, Yoshida CF, Lampe E. Detection of hepatitis C virus in platelets: evaluating its relationship to viral and host factors. Hepatogastroenterology. 2007;54(75): 964-968.
. Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther. 2007;26(s1): 13-19.
. Wang, C, Yao W, Wang S, Chang T, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis. 2004;39(6): 790-796.
. Linares M, Pastor E, Hernandez F, Montagud M, Blanquer A. Autoimmune thrombocytopenia and hepatitis C virus infection. Am J Hematol. 1996;53(4): 284-284.
. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol. 1996;24(2): 135-140.
. Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol. 2001;68(3): 202-209.
. Olariu M, Olariu C, Olteanu D. Thrombocytopenia in chronic hepatitis C. J Gastrointestin Liver Dis. 2010;19(4): 381-385.
. Iga D, Tomimatsu M, Endo H, Ohkawa S, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-α therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol. 2005;75(5): 417-423.
. Haqqi A, Munir R, Khalid M, et al. Prevalence of hepatitis C virus genotypes in Pakistan: current scenario and review of literature. Viral Immunol. 2019;32(9): 402-413.
. Ali R, Ashfaq M, Bukhari MA, Shahzad A. Mucocutaneous manifestations in hepatitis C patients. J Pak Asso Dermatol. 2016;24(1): 40-45.
. Bano S, Qureshi J, Raza A, Hashmi KZ. Thrombocytopenia as a clinical manifestation of hepatitis C among patients with a positive Anti-HCV test. Int J Infect. 2016;3(3): e35094.
. Behnava B, Alavian S-M, Ahmadzad-Asl M. The prevalence of thrombocytopenia in patients with chronic hepatitis B and C. Hepatitis Mon. 2006;6(2): 67-69.
. García J-S, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez M-M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant α2b-interferon therapy. Bri J Haematol. 2000;110(1): 98-103.
. Dai C-Y, Ho C, Huang J, et al., Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2010;52(2): 160-166.
. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001;96(11): 3142-3146.
. Khokhar N. Serum aminotransferase levels and platelet count as predictive factor of fibrosis and cirrhosis in patients with chronic hepatitis C infection. J Pak Medical Assoc. 2003;53(3): 101-103.
Copyright (c) 2020 Kanwal Sarwar, Sarmad Zahoor Zahoor, Imran Tipu
This work is licensed under a Creative Commons Attribution 4.0 International License.
BSR follows an open-access publishing policy and full text of all published articles is available free, immediately upon publication of an issue. The journal’s contents are published and distributed under the terms of the Creative Commons Attribution 4.0 International (CC-BY 4.0) license. Thus, the work submitted to the journal implies that it is original, unpublished work of the authors (neither published previously nor accepted/under consideration for publication elsewhere). On acceptance of a manuscript for publication, a corresponding author on the behalf of all co-authors of the manuscript will sign and submit a completed the Copyright and Author Consent Form.
